Methods of treating a subject for a condition

• US 10,086,071 B2
• Filed: 09/24/2013
• Issued: 10/02/2018
• Est. Priority Date: 08/11/2004
• Status: Active Grant

• Current Assignee: Palo Alto Investors
• Original Assignee: Palo Alto Investors
• Inventors: Yun, Anthony Joonkyoo, Lee, Patrick Yuarn-Bor
• Primary Examiner(s): Hui, San Ming R
• Application Number:
  US14/035,814
• Publication Number:
  US 20140086872A1
• Time in Patent Office: 1,834 Days
• Field of Search: 514423
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/4178 not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 31/60 Salicylic acid; Derivatives thereof
• CPC Class Codes: A61K 38/212 IFN-alpha
• CPC Class Codes: A61K 38/215 IFN-beta
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 38/482 Serine endopeptidases (3.4.21)
• CPC Class Codes: A61K 38/49 Urokinase; Tissue plasminogen activator
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Methods are provided for treating a subject for at least one condition that includes inflammation, a blood clotting condition and autonomic nervous system dysfunction such as adrenergia, e.g., simultaneously. Also provided are kits for use in practicing the subject methods.

Claims

1. A method of treating a subject for osteoarthritis, said method comprising:

(a) identifying said osteoarthritis; and

(b) administering an effective amount of an autonomic nervous system modulator to said subject to treat said subject for said osteoarthritis, wherein said autonomic nervous system modulator is an antiadrenergic agent and said antiadrenergic agent is an angiotensin converting enzyme (“

ACE”

) inhibitor.

2. A method of treating a subject for osteoarthritis, the method comprising pharmacologically modulating at least a portion of the autonomic nervous system of said subject to increase the parasympathetic activity/sympathetic activity ratio in a manner effective to treat said subject for said osteoarthritis, wherein said pharmacological modulation comprises administering an effective amount of an autonomic nervous system modulator and wherein said autonomic nervous system modulator is an angiotensin converting enzyme (“

ACE”

) inhibitor.